分组1 - Mission Produce, Inc. (AVO) closed at $11.76, with a 0.2% gain over the past four weeks, and a mean price target of $17.33 indicates a 47.4% upside potential [1] - The average price targets range from a low of $17.00 to a high of $18.00, with a standard deviation of $0.58, suggesting a 44.6% to 53.1% upside from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] 分组2 - The Zacks Consensus Estimate for the current year has increased by 15.7% over the last 30 days, with no negative revisions [12] - AVO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of AVO's potential gains, it does suggest a positive price movement direction [14]

Core Viewpoint - MBX Biosciences, Inc. (MBX) has shown significant stock price appreciation of 54.6% over the past four weeks, with a mean price target of $60.29 indicating a potential upside of 280.1% from the current price of $15.86 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $18.94, where the lowest estimate of $30.00 suggests an 89.2% increase, and the highest estimate of $84.00 indicates a potential surge of 429.6% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about MBX's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 2.7% rise in the Zacks Consensus Estimate for the current year [12] - MBX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While the consensus price target is often sought after, it is important to approach it with skepticism, as empirical research indicates that price targets can mislead investors [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - UBS has set a price target of $255 for Assurant, indicating a potential upside of approximately 17.9% from the current stock price of $216.29 [1] Group 1: Financial Performance - Assurant is set to announce its third-quarter financial results on November 4, 2025, after market close, with a conference call scheduled for the following morning [2] - The upcoming financial results are expected to influence the stock's performance and investor sentiment [2] Group 2: Stock Performance - Currently, Assurant's stock price is $216.29, reflecting a decrease of $5.40 or approximately -2.44% [3] - The stock has traded between $216.21 and $223.65 today, with a yearly high of $230.55 and a low of $174.97, indicating volatility [3] Group 3: Market Capitalization - Assurant's market capitalization is approximately $10.91 billion, with a trading volume of 365,113 shares on the NYSE, reflecting the company's size and investor interest [4] - The upcoming financial results could impact the market capitalization and trading volume depending on the company's performance [4]

Core Viewpoint - Lakeland Industries (LAKE) shows significant upside potential with a mean price target of $24.25, indicating a 63.9% increase from the current price of $14.8 [1] Price Targets - The average price target consists of four estimates ranging from a low of $20.00 to a high of $27.00, with a standard deviation of $3.1, suggesting a consensus among analysts [2] - The lowest estimate indicates a 35.1% increase, while the highest suggests an 82.4% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on LAKE's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has been correlated with near-term stock price movements, reinforcing the optimistic outlook [11] Earnings Estimates - Over the past 30 days, one earnings estimate has increased, leading to a Zacks Consensus Estimate rise of 177.8% [12] - LAKE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of LAKE's potential gains, it does provide a useful guide for price movement direction [14]

Core Viewpoint - Perpetua Resources Corp. (PPTA) shows potential for further upside, with a mean price target of $25.73 indicating a 27.2% increase from the current price of $20.23 [1] Price Targets - The average price target consists of five estimates ranging from a low of $21.00 to a high of $30.00, with a standard deviation of $3.68, suggesting variability in analyst predictions [2] - The lowest estimate indicates a 3.8% increase, while the highest suggests a 48.3% upside [2] Analyst Sentiment - There is strong agreement among analysts regarding PPTA's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has increased by 16% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - PPTA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be wise due to historical inaccuracies in predicting stock price movements [3][7][10] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8]

Core Insights - Harrow, Inc. has garnered investor attention with a recent price target of $70 set by Thomas Flaten from Lake Street, indicating a potential increase of approximately 48.62% from the current stock price of $47.10 [1] - The company held its Analyst/Investor Day on September 26, 2025, where key executives provided insights into its strategic direction and financial outlook, attended by analysts from notable firms [2] - The stock price of HROW has recently increased by $0.95, or 2.06%, with a trading range on the same day between $46.29 and $50.72, reflecting significant volatility over the past year [3] - Harrow's market capitalization stands at approximately $1.74 billion, with a trading volume of 1,326,594 shares, indicating strong investor interest and potential upside [4]

Core Viewpoint - US Gold Corp (USAU) has shown a significant price increase of 13.3% over the past four weeks, with a mean price target of $19.5 indicating a potential upside of 29% from the current price of $15.12 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.27, where the lowest estimate is $15.00 (indicating a 0.8% decline) and the highest estimate is $23.50 (indicating a 55.4% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - There is a strong consensus among analysts regarding the company's ability to report better earnings, with a 17.8% increase in the Zacks Consensus Estimate for the current year [11][12] - USAU holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to potential biases and inflated targets set by analysts [3][8][10]

Group 1 - Photronics (PLAB) shares have increased by 11.1% over the past four weeks, closing at $24.73, with a mean price target of $31.65 indicating a potential upside of 28% [1] - The mean estimate includes three short-term price targets with a standard deviation of $1.51, where the lowest estimate suggests a 21.3% increase and the highest indicates a 33.2% surge [2] - Analysts show a strong consensus that PLAB will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for PLAB has increased by 7.7% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - PLAB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [14]

Core Viewpoint - MBX Biosciences, Inc. (MBX) shares have increased by 44% in the past four weeks, closing at $20, with a mean price target of $37.71 indicating a potential upside of 88.6% according to Wall Street analysts [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $4.23, where the lowest estimate is $30.00 (50% increase) and the highest is $44.00 (120% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, indicating less variability in their estimates [2][9] Earnings Estimates and Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - The Zacks Consensus Estimate for the current year has risen by 2.7% over the past month, with one estimate increasing and no negative revisions [12] Zacks Rank and Investment Potential - MBX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - Edgewise Therapeutics, Inc. (EWTX) shows significant upside potential with a mean price target of $39.17, indicating an 182% increase from the current price of $13.89 [1][11]. Price Targets and Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $12.96, suggesting variability among analysts [2]. - The lowest estimate is $14.00, indicating a modest 0.8% increase, while the highest estimate is $51.00, reflecting a potential surge of 267.2% [2]. - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9]. Earnings Estimates - Analysts have shown increasing optimism about EWTX's earnings prospects, with a strong consensus on higher EPS estimates [11]. - The Zacks Consensus Estimate for the current year has increased by 1% over the past month, with one estimate rising and no negative revisions [12]. - EWTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8]. - While price targets can provide insights, they should be approached with skepticism as they may not accurately predict stock price movements [10].